Skip to main content
. Author manuscript; available in PMC: 2022 May 2.
Published in final edited form as: Lancet Child Adolesc Health. 2021 Feb 12;5(4):274–283. doi: 10.1016/S2352-4642(21)00020-1

Figure 1: Prevalence of moderate or severe cisplatin-induced hearing loss by age and underlying malignancy.

Figure 1:

Prevalence of hearing loss at latest audiometry by age at cancer diagnosis in years (A) and underlying malignancy (B). χ2 tested for differences by age in part A and by category in part B; p<0.001 in both. SIOP=International Society of Pediatric Oncology Ototoxicity Grade (0–4).